Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog

Bunzo Matsuura, Maoqing Dong, Bernard Coulie, Delia I. Pinon, Laurence J Miller

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The motilin receptor belongs to a group of class I G protein-coupled receptors that also includes the growth hormone secretagogue and ghrelin receptors. These represent clinically useful targets for pharmacotherapy. Their potentially unique structures and the molecular basis of their binding are not yet clear. We previously reported the initial affinity labeling of a region within this receptor (a cyanogen bromide fragment extending from the first to the second extracellular loop) using a position 1 photolabile motilin analog. To extend our understanding of the molecular basis of motilin binding, we have developed an additional radioiodinatable motilin analog probe having site of covalent attachment in position 5. This was a full agonist that bound to the motilin receptor specifically and with high affinity, and that efficiently established a single covalent bond to its receptor. Sequential chemical and enzymatic cleavage of labeled wild-type and mutant motilin receptor constructs established that the region of labeling was within the third extracellular loop. This was further localized to Phe332 using radiochemical Edman degradation sequencing. These data provide the first spatial approximation constraint that can be used in the docking of this peptide ligand to its receptor. We hope that a series of such constraints can be determined to provide adequate structural information to begin to elucidate the conformation of this agonist-bound receptor and to ultimately be useful in the rational design of drugs acting at this important target.

Original languageEnglish (US)
Pages (from-to)1101-1108
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume313
Issue number3
DOIs
StatePublished - Jun 2005

Fingerprint

Motilin
Ghrelin Receptor
Cyanogen Bromide
Drug Design
G-Protein-Coupled Receptors
Molecular Structure
Ligands
Drug Therapy
Peptides
motilin receptor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog. / Matsuura, Bunzo; Dong, Maoqing; Coulie, Bernard; Pinon, Delia I.; Miller, Laurence J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 313, No. 3, 06.2005, p. 1101-1108.

Research output: Contribution to journalArticle

@article{008768048ea3477cba513c4c8d5c28d2,
title = "Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog",
abstract = "The motilin receptor belongs to a group of class I G protein-coupled receptors that also includes the growth hormone secretagogue and ghrelin receptors. These represent clinically useful targets for pharmacotherapy. Their potentially unique structures and the molecular basis of their binding are not yet clear. We previously reported the initial affinity labeling of a region within this receptor (a cyanogen bromide fragment extending from the first to the second extracellular loop) using a position 1 photolabile motilin analog. To extend our understanding of the molecular basis of motilin binding, we have developed an additional radioiodinatable motilin analog probe having site of covalent attachment in position 5. This was a full agonist that bound to the motilin receptor specifically and with high affinity, and that efficiently established a single covalent bond to its receptor. Sequential chemical and enzymatic cleavage of labeled wild-type and mutant motilin receptor constructs established that the region of labeling was within the third extracellular loop. This was further localized to Phe332 using radiochemical Edman degradation sequencing. These data provide the first spatial approximation constraint that can be used in the docking of this peptide ligand to its receptor. We hope that a series of such constraints can be determined to provide adequate structural information to begin to elucidate the conformation of this agonist-bound receptor and to ultimately be useful in the rational design of drugs acting at this important target.",
author = "Bunzo Matsuura and Maoqing Dong and Bernard Coulie and Pinon, {Delia I.} and Miller, {Laurence J}",
year = "2005",
month = "6",
doi = "10.1124/jpet.104.081562",
language = "English (US)",
volume = "313",
pages = "1101--1108",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog

AU - Matsuura, Bunzo

AU - Dong, Maoqing

AU - Coulie, Bernard

AU - Pinon, Delia I.

AU - Miller, Laurence J

PY - 2005/6

Y1 - 2005/6

N2 - The motilin receptor belongs to a group of class I G protein-coupled receptors that also includes the growth hormone secretagogue and ghrelin receptors. These represent clinically useful targets for pharmacotherapy. Their potentially unique structures and the molecular basis of their binding are not yet clear. We previously reported the initial affinity labeling of a region within this receptor (a cyanogen bromide fragment extending from the first to the second extracellular loop) using a position 1 photolabile motilin analog. To extend our understanding of the molecular basis of motilin binding, we have developed an additional radioiodinatable motilin analog probe having site of covalent attachment in position 5. This was a full agonist that bound to the motilin receptor specifically and with high affinity, and that efficiently established a single covalent bond to its receptor. Sequential chemical and enzymatic cleavage of labeled wild-type and mutant motilin receptor constructs established that the region of labeling was within the third extracellular loop. This was further localized to Phe332 using radiochemical Edman degradation sequencing. These data provide the first spatial approximation constraint that can be used in the docking of this peptide ligand to its receptor. We hope that a series of such constraints can be determined to provide adequate structural information to begin to elucidate the conformation of this agonist-bound receptor and to ultimately be useful in the rational design of drugs acting at this important target.

AB - The motilin receptor belongs to a group of class I G protein-coupled receptors that also includes the growth hormone secretagogue and ghrelin receptors. These represent clinically useful targets for pharmacotherapy. Their potentially unique structures and the molecular basis of their binding are not yet clear. We previously reported the initial affinity labeling of a region within this receptor (a cyanogen bromide fragment extending from the first to the second extracellular loop) using a position 1 photolabile motilin analog. To extend our understanding of the molecular basis of motilin binding, we have developed an additional radioiodinatable motilin analog probe having site of covalent attachment in position 5. This was a full agonist that bound to the motilin receptor specifically and with high affinity, and that efficiently established a single covalent bond to its receptor. Sequential chemical and enzymatic cleavage of labeled wild-type and mutant motilin receptor constructs established that the region of labeling was within the third extracellular loop. This was further localized to Phe332 using radiochemical Edman degradation sequencing. These data provide the first spatial approximation constraint that can be used in the docking of this peptide ligand to its receptor. We hope that a series of such constraints can be determined to provide adequate structural information to begin to elucidate the conformation of this agonist-bound receptor and to ultimately be useful in the rational design of drugs acting at this important target.

UR - http://www.scopus.com/inward/record.url?scp=19444381509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444381509&partnerID=8YFLogxK

U2 - 10.1124/jpet.104.081562

DO - 10.1124/jpet.104.081562

M3 - Article

C2 - 15677347

AN - SCOPUS:19444381509

VL - 313

SP - 1101

EP - 1108

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -